Omeros Corporation (OMER) News
Follow Omeros Corporation (OMER) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Omeros Q3'26 Results Due November 11
Omeros is expected to report Q3'26 results on November 11; revenue and EPS estimates were provided.
EQUITY | Nov 04, 2026, 12:00 PM UTC
M
Omeros Shares Fall 15% After CHMP Upholds Negative Drug Opinion
Omeros shares fell 15% on Friday after an EMA committee upheld a negative opinion on its drug for a serious post-transplant condition. H.C. Wainwright called the selloff overdone.
EQUITY | Oct 16, 2026, 07:24 PM UTC
M
EMA Issues Second Negative Opinion on Omeros’ Narsoplimab Application
The European Medicines Agency issued a negative opinion on Omeros’ marketing application for narsoplimab, its treatment for stem cell transplant-associated complications. The decision marks the second negative opinion in
REGULATION | Oct 16, 2026, 12:01 PM UTC
M
EMA Upholds Negative Opinion on Omeros’ Narsoplimab Application
The EMA committee upheld its negative opinion on Omeros’ marketing authorization application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy.
REGULATION | Oct 16, 2026, 10:56 AM UTC
M
EU Panel Upholds Negative Opinion on Omeros Narsoplimab Application
The European Medicines Agency’s CHMP upheld its negative opinion on Omeros’ narsoplimab application for TA-TMA after re-examination. Omeros also plans to end its compassionate-use program, while current patients will rec
REGULATION | Oct 16, 2026, 10:55 AM UTC
M
Omeros Receives Negative EU Opinion on Narsoplimab
Omeros said the EMA’s CHMP issued a negative opinion on its EU marketing application for narsoplimab in TA-TMA after re-examination. The drug is FDA-approved in the U.S. as YARTEMLEA.
REGULATION | Oct 16, 2026, 10:21 AM UTC
M
Omeros Receives Negative CHMP Opinion on Narsoplimab Application
The EMA’s CHMP issued a negative opinion on Omeros’ marketing authorization application for narsoplimab following re-examination.
REGULATION | Oct 16, 2026, 10:21 AM UTC
L
Omer H1 Net Profit €6.1 Mln
Omer Spa MIL:OMER
NEWS | Sep 28, 2026, 12:27 PM UTC
L
Weekly Recap: Yartemlea U.S. forecast raised and Omeros hits 52-week high
Omeros Corporation (NASDAQ:OMER) shares jumped to a 52-week high near $20.68 after analysts raised peak U.S. sales for its drug Yartemlea to about $400M, forecasting a 35—40% U.S. market share while expecting minimal Eur
EARNINGS | Sep 28, 2026, 11:06 AM UTC
M
Natera hits Japan regulatory approval milestone; Omeros reaches 5-year peak
Natera shares rose after Japan regulatory approval for its cancer test; Omeros shares gained after a Cantor Fitzgerald upgrade and optimism around its lead drug’s commercialization.
EQUITY | Sep 22, 2026, 05:51 PM UTC
H
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE: ONON ) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter
LIVE | Sep 22, 2026, 02:25 PM UTC
M
Cantor Fitzgerald upgrades Omeros to Overweight; $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22.00 price target, implying 19.0% upside versus the Sep 21 close of $18.49.
EQUITY | Sep 22, 2026, 10:50 AM UTC
L
Omeros VP General Counsel sold shares worth $929,667
Peter B. Cancelmo, VP and General Counsel at Omeros, sold common stock in two transactions at weighted average prices of $18.6451 and $18.5416 per share, totaling $929,667.
EQUITY | Sep 01, 2026, 08:51 PM UTC
L
Premarket gainers list led by GXAI, CURI and IVDA
A premarket movers list shows GXAI, CURI, IVDA, HLIT, OMER, FGI, BIVI, FRGT, ONDG and HHS among the top percentage gainers, with no catalyst supplied.
EQUITY | Aug 13, 2026, 09:43 AM UTC
L
Omeros shares rise after second-quarter earnings beat estimates
Omeros Corp. shares rise in pre-market trading after the company reported second-quarter earnings of 2 cents per share and sales of $28.529 million, both above analyst estimates.
EARNINGS | Aug 13, 2026, 09:16 AM UTC
L
Omeros Q2 Adj. EPS Beats Estimate
Omeros reports Q2 adjusted EPS of $0.02, beating the estimate of $(0.27)
EARNINGS | Aug 12, 2026, 08:09 PM UTC
H
US: Omeros Corp Gets NTAP Status for Yartemlea
Omeros Corp gets NTAP status for Yartemlea
EQUITY | Aug 03, 2026, 12:33 PM UTC
L
OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopath
OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopathy. Note Omeros markets Yartemlea (narsoplimab), which is approved for hematopoie
EQUITY | Jul 27, 2026, 04:09 PM UTC
H
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in decline amid weakness in tech stocks. Still, the market has reacted positively to easing geopolitical tensions and a steep declin
MACRO | Jul 27, 2026, 03:56 PM UTC
L
Omeros up 11% to $10.89 after AstraZeneca study failure
Omeros up 11% to $10.89 after AstraZeneca study failure
EQUITY | Jul 27, 2026, 02:13 PM UTC
L
OMER EMA: upon receipt of grounds of Omeros Ireland's request, will Re-examine opinion on yartemlea & issue final recommendation
OMER EMA: upon receipt of grounds of Omeros Ireland's request, will Re-examine opinion on yartemlea & issue final recommendation
EQUITY | Jul 15, 2026, 12:37 PM UTC
L
OMER EMA: Omeros Ireland requested Re-examination of EMA's opinion on yartemlea issued on 25 June - website
OMER EMA: Omeros Ireland requested Re-examination of EMA's opinion on yartemlea issued on 25 June - website
EQUITY | Jul 15, 2026, 12:36 PM UTC
L
Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About
NEW YORK CITY, NY / / July 3, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on
EQUITY | Jul 03, 2026, 03:01 PM UTC
H
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ: IVF ) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings came out 4 days ag
EARNINGS | Jun 26, 2026, 05:05 PM UTC
H
Oil Falls 4%
Crude oil prices fall 4% to $69.05, while US consumer sentiment rises to 49.5 in June
COMMODITIES | Jun 26, 2026, 04:17 PM UTC
H
OMER: EMA Rejects Narsoplimab
The European Medicines Agency's Human Medicines Committee issues a negative opinion for Omeros Corp.'s narsoplimab for stem cell transplant-associated thrombotic microangiopathy
EQUITY | Jun 26, 2026, 03:16 PM UTC
M
OMER Updates EU Application
Omeros Corporation announces update on European marketing authorization application for Narsoplimab in TA-TMA
EQUITY | Jun 26, 2026, 12:38 PM UTC
H
OMER Gets EMA CHMP Negative Opinion
Omeros Corporation receives a negative opinion from the EMA CHMP on its marketing authorization application for narsoplimab in TA-TMA
REGULATION | Jun 26, 2026, 12:33 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Friday's pre-market session, with gainers including Quantum Cyber and INVO Fertility, and losers including Creative Medical Tech and Omeros
EQUITY | Jun 26, 2026, 12:05 PM UTC